DE69609820T2 - Verwendung von substituirten Pyridinverbindungen zur Behandlung der atopischen Dermatitis und der Kontaktdermatitis - Google Patents

Verwendung von substituirten Pyridinverbindungen zur Behandlung der atopischen Dermatitis und der Kontaktdermatitis

Info

Publication number
DE69609820T2
DE69609820T2 DE69609820T DE69609820T DE69609820T2 DE 69609820 T2 DE69609820 T2 DE 69609820T2 DE 69609820 T DE69609820 T DE 69609820T DE 69609820 T DE69609820 T DE 69609820T DE 69609820 T2 DE69609820 T2 DE 69609820T2
Authority
DE
Germany
Prior art keywords
dermatitis
treatment
substituted pyridine
pyridine compounds
atopic dermatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69609820T
Other languages
English (en)
Other versions
DE69609820D1 (de
Inventor
Edgar Grisworld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
SmithKline Beecham Corp
Original Assignee
GlaxoSmithKline LLC
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC, SmithKline Beecham Corp filed Critical GlaxoSmithKline LLC
Application granted granted Critical
Publication of DE69609820D1 publication Critical patent/DE69609820D1/de
Publication of DE69609820T2 publication Critical patent/DE69609820T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
DE69609820T 1995-03-02 1996-02-29 Verwendung von substituirten Pyridinverbindungen zur Behandlung der atopischen Dermatitis und der Kontaktdermatitis Expired - Fee Related DE69609820T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39746195A 1995-03-02 1995-03-02
PCT/US1996/002950 WO1996026725A1 (en) 1995-03-02 1996-02-29 Method for treating atopic dermatitis and contact dermatitis

Publications (2)

Publication Number Publication Date
DE69609820D1 DE69609820D1 (de) 2000-09-21
DE69609820T2 true DE69609820T2 (de) 2001-03-08

Family

ID=23571295

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69609820T Expired - Fee Related DE69609820T2 (de) 1995-03-02 1996-02-29 Verwendung von substituirten Pyridinverbindungen zur Behandlung der atopischen Dermatitis und der Kontaktdermatitis

Country Status (5)

Country Link
EP (1) EP0812194B1 (de)
JP (1) JPH11501038A (de)
DE (1) DE69609820T2 (de)
DK (1) DK0812194T3 (de)
WO (1) WO1996026725A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229493B1 (ko) 2005-10-26 2013-02-04 삼성전자주식회사 기록 방지 기능을 효과적으로 수행할 수 있는 정보 저장매체, 기록/재생 장치 및 기록/재생 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2573592A (en) * 1991-09-19 1993-04-27 Smithkline Beecham Corporation Pyridine compounds for treating leukotriene-related diseases
IL106156A0 (en) * 1992-06-30 1993-10-20 Smithkline Beecham Corp Pyridinyl compounds

Also Published As

Publication number Publication date
EP0812194A4 (de) 1998-03-11
WO1996026725A1 (en) 1996-09-06
EP0812194A1 (de) 1997-12-17
DE69609820D1 (de) 2000-09-21
EP0812194B1 (de) 2000-08-16
JPH11501038A (ja) 1999-01-26
DK0812194T3 (da) 2000-12-18

Similar Documents

Publication Publication Date Title
DE69622074D1 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
DE69435321D1 (de) Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69722681D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen darmerkrankungen
DE69432299D1 (de) Multiple Botulinum Toxine zur Behandlung von neuromuskulären Störungen und Zuständen
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE275608T1 (de) Behandlung von mineralfüllstoffen mit phosphaten, diese füllstoffe und deren verwendung
DE69733329D1 (de) Verwendung von Taurin zur Behandlung oder Vorbeugung von ischämischen Verletzungen
DE69212620T2 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69912670D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69621447T2 (de) Verwendung von nitroflavonoide zur behandlung von angstzuständen
DE59705697D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69701458T2 (de) Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen
DE69418931D1 (de) Verwendung von VIP und deren Analogen und Fragmenten zur Behandlung von neurodegenerativen Krankheiten
DE69609820T2 (de) Verwendung von substituirten Pyridinverbindungen zur Behandlung der atopischen Dermatitis und der Kontaktdermatitis
DE69412178D1 (de) Apparat zur Behandlung von Lagen
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE69715878T2 (de) Formulierung zur behandlung und/oder vorbeugung von dementia
ATA93695A (de) Mittel zur behandlung von strahlenschäden
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
DE69714424D1 (de) Verwendung von kolostrum zur behandlung von darmverstopfung
ATA14996A (de) Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
DE69302250D1 (de) Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee